Document Detail


Combined approaches for HIV cure.
MedLine Citation:
PMID:  23446138     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: A serious effort has begun to develop therapies that may be capable of eradicating established HIV infection in man. Because of the biological complexity of HIV infection that persists despite potent antiretroviral therapy, it is widely believed that if such therapies can be developed they will involve complex, multimodality approaches. We highlight some of the recent studies in this effort.
RECENT FINDINGS: An inhibitor of histone deacetylase has been demonstrated to disrupt latency in man, and new histone deacetylase inhibitors have been identified. Other potential targets, such as histone methyltransferase, protein kinase C, and BRD4, have been recently studied. Model systems, both in primary cells and in animal models, are beginning to be validated. In the clinic, immune-based therapies to aid in the clearance of persistent infection are also being tested.
SUMMARY: It is too early to know what combination eradication therapies for HIV infection will look like in the future, but candidate therapies and model systems to perform preclinical validation are beginning to take shape.
Authors:
David M Margolis; Daria J Hazuda
Related Documents :
17568688 - Is pre-eclampsia less common in patients with hiv/aids?
8894398 - The spectrum of osteoarticular and soft tissue changes in patients with human immunodef...
23121278 - Safety of pharmacoenhancers for hiv therapy.
11023778 - What's new in hiv
17604548 - A nascent hiv type 1 epidemic among injecting drug users in kabul, afghanistan is domin...
20738778 - Increased pd-1 and decreased cd28 expression in chronic hepatitis b patients with advan...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current opinion in HIV and AIDS     Volume:  8     ISSN:  1746-6318     ISO Abbreviation:  Curr Opin HIV AIDS     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-11     Completed Date:  2013-09-25     Revised Date:  2014-05-07    
Medline Journal Info:
Nlm Unique ID:  101264945     Medline TA:  Curr Opin HIV AIDS     Country:  United States    
Other Details:
Languages:  eng     Pagination:  230-5     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Retroviral Agents / therapeutic use*
Drug Therapy, Combination
HIV Infections / drug therapy*,  virology
HIV-1 / physiology*
Humans
Virus Physiological Processes / drug effects
Grant Support
ID/Acronym/Agency:
AI082608/AI/NIAID NIH HHS; AI50410/AI/NIAID NIH HHS; DA030156/DA/NIDA NIH HHS; MH085597/MH/NIMH NIH HHS; P30 AI050410/AI/NIAID NIH HHS; R00046//PHS HHS; R01 DA030156/DA/NIDA NIH HHS; R01 MH085597/MH/NIMH NIH HHS; U19 AI082608/AI/NIAID NIH HHS; UL1 RR025747/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Retroviral Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neck muscle cross-sectional area, brain volume and cognition in healthy older men: a cohort study.
Next Document:  CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.